Objective: Antinuclear antibodies (ANA) represent a hallmark in the diagnosis of ANAassociated rheumatic diseases (AARD). However, anti-DFS70 antibodies are present in a higher portion of the healthy individuals (HI) than in patients with AARD. Consequently, we developed a novel, highly specific indirect immunofluorescence (IIF) method that blocks anti-DFS70 antibodies from binding to HEp-2 cells and to evaluate the method in a multicenter study. Methods: A total of 18 samples from systemic lupus erythematosus patients (SLE, n ¼ 7) and HI (n ¼ 11) were used for the initial development of the immunoadsorption method. For the multi-center evaluation, samples with a dense fine speckled (DFS) pattern (n ¼ 99) were collected at three different sites based on their established IIF screening procedure at the respective laboratories. Additionally, four characterized samples with established clinically relevant IIF patterns (centromere, nucleolar, speckled, homogeneous) were blended in five different ratios (10%, 25%, 50%, 75%, 90%) with a sample positive for anti-DFS70 antibodies, which by itself showed a dense fine speckled (DFS) IIF pattern. All samples were tested by IIF with NOVA Lite HEp-2 ANA and NOVA Lite HEp-2 Select on the NOVA View Õ instrument, and also tested by QUANTA Flash DFS70 chemiluminescent immunoassay (CIA) for confirmation of anti-DFS70 antibodies (Inova Diagnostics, San Diego, CA, USA). Results: For the development of the immunoadsorption method, only 1/7 ANA-positive samples from SLE patients, but 8/10 ANA-positive samples from healthy individuals turned negative using the immunoadsorption. Subsequently, 73/99 (73.7%) of the DFS pattern samples were positive by CIA for anti-DFS70 antibodies showing a strong quantitative Spearman's correlation (rho ¼ 0.57 (95% CI, 0.39-0.71, p < 0.0001)) between light intensity units (LIU) measured by NOVA View and CIA. Intensities measured with NOVA Lite HEp-2 and NOVA Lite HEp-2 Select demonstrated significantly lower intensity values after inhibition with DFS70 antigen (p < 0.0001). When samples were processed to mimic samples with mixed patterns (DFS þ clinically relevant pattern), the new immunoadsorption method demonstrated that all clinically relevant patterns remained unchanged whereas the LIUs from NOVA View analysis significantly decreased after inhibition (p < 0.0001). Conclusion: The data showed that the NOVA Lite HEp-2 Select kit effectively inhibits anti-DFS70 antibody binding to its cellular target antigen. Lupus (2016) 25, 897-904.
Introduction
The presence of antinuclear antibodies (ANA), directed against intracellular antigens is a serological hallmark in the diagnosis of ANA-associated systemic autoimmune rheumatic diseases (AARD). 1 The indirect immunofluorescence (IIF) assay on HEp-2 cells is among the most commonly used routine test for ANA detection and has been recommended as the screening test of choice by a study group of the American College of Rheumatology (ACR). 2 However, besides numerous advantages of the ANA HEp-2 test, the method also has several limitations, especially limited specificity for AARD, which is primarily related to anti-dense fine speckled 70 (anti-DFS70) antibodies. Historically, these autoantibodies were reported as an ANA IIF pattern in the serum of a patient with interstitial cystitis, 3 but were later associated with various other conditions including chronic inflammatory conditions (reviewed in 4 ), cancer, 5 autoimmune thyroiditis, 6 obstetric complications marked by thrombosis 7 and were even found in healthy individuals (HI). 8, 9 The typical DFS IIF staining pattern is recognized as uniformly distributed fine speckles throughout interphase nuclei and on metaphase chromatin. 10 The antigen was initially termed DFS70 according to the IIF pattern and the molecular weight as determined by western immunoblots, but the primary target autoantigen was later identified as the lens epithelium-derived growth factor (LEDGF) 11 and more recently as the DNA binding transcription coactivator p75 (reviewed in 4 ). DFS70/LEDGF is highly expressed in prostate tumor tissues 5 and has a number of physiological functions including serving as a cofactor for human immunodeficiency virus replication through an interaction with viral integrase. 12 The highest prevalence of anti-DFS70 antibodies has been reported in patients with Vogt-Harada syndrome (66.7%) 13 and atopic dermatitis (AD, 30%) 3, 14 followed by HI (10%), 4, 8 while the prevalence in AARD is significantly lower (2-3%). Considering the prognostic aspect of most ANAs, it was recently reported that none of 40 HI with isolated anti-DFS70 reactivity developed an AARD within an average four-year follow-up. 15 Therefore, it was suggested that the presence of isolated anti-DFS70 antibodies could be taken as strong evidence against a diagnosis of AARD such as systemic lupus erythematosus (SLE). 8, [15] [16] [17] Since ANAs and related autoantibodies are generally considered useful biomarkers for AARD and are included in the classification criteria for SLE 18 and systemic sclerosis (SSc), 19 ANA testing on HEp-2 substrates may lead to inappropriate referrals to tertiary care specialists, as well as anxiety in patients and physicians alike 15 and, perhaps, inappropriate and potentially toxic therapies. 20 Several studies over the past years have reported on clinical and technical aspects of anti-DFS70 antibody detection; however, very little data are available on the immunoadsorption of anti-DFS70 antibodies by the cognate purified protein.
Based on the observation that the presence of anti-DFS70 antibodies are often misinterpreted as indicating a diagnosis of AARD, the concept of blocking anti-DFS70 antibodies from binding to their natural antigen in IIF on HEp-2 cells was appealing. Accordingly, the principal aims of this study were to develop a method for the adsorption of anti-DFS70 antibodies from sera in the context of IIF testing on HEp-2 cells. The principal aims were to determine the prevalence of anti-DFS70 autoantibodies in samples with a DFS IIF pattern, and to analyze the efficiency of immunoadsorption of anti-DFS70 autoantibodies on HEp-2 cell substrates. Lastly, we investigated the benefit of immunoadsorption in samples with mixed IIF patterns to determine any effects on autoantibodies that are known to be highly associated with AARD.
Materials and methods

Serum samples
For the initial development of the immunoadsorption method, a total of 18 samples from HI (n ¼ 11) and from SLE patients (n ¼ 7) were obtained. For the method validation, samples with the DFS IIF pattern (n ¼ 99) were collected from three different sites based on their established IIF screening procedure at the respective laboratory: RDL Reference Laboratory (Los Angeles, CA, USA), Southampton General Hospital (Southampton, UK) and Medical University of Gdansk (Gdansk, Poland). Additional details and the number of samples included from each site can be found in Table 1 . Patient data were anonymized in accordance with the latest version of the Helsinki Declaration of human research ethics. Additionally, four characterized serum samples (Inova serum bank) with established clinically relevant IIF patterns (centromere, nucleolar, nuclear speckled, nuclear homogeneous) were blended in five different ratios (10%, 25%, 50%, 75%, and 90% serum ratios) with a sample positive for anti-DFS70 antibodies, which by itself showed a dense fine speckled (DFS) pattern. All samples were tested by IIF with NOVA Lite HEp-2 ANA and NOVA Lite HEp-2 Select on the NOVA View Õ instrument, an automated fluorescent microscope (Inova Diagnostics, San Diego, CA, USA). Development and multi-center evaluation C Bentow et al.
Immunofluorescence assays (IIF) and immunoadsorption
Samples were identified at the three participating sites using HEp-2 substrates from different manufacturers (see Table 1 ). Immunoadsorption was performed on HEp-2 cells following the protocol of NOVA Lite HEp-2 Select (Inova Diagnostics).
In brief: Sample diluent containing recombinant DFS70 antigen (expressed in E.coli with purity of >0.95%) was used to dilute patient serum samples. Prior to application of the diluted samples onto the HEp-2 substrate, diluted samples were incubated for 30 minutes. The subsequent assay procedure was identical to common IIF procedures. Results were interpreted using NOVA View (Inova Diagnostics), an automated digital image analysis system which is used for acquiring, analyzing, and interpreting ANA testing on HEp-2 cells, based on measured light intensity units (LIUs) and pattern recognition. 21 Although the LIUs generated by the NOVA View system are not the final result, the LIU values were used in the analysis for this study as a scientific tool to compare LIU before and after immunoadsorption.
Chemiluminescence anti-DFS70 assays
All samples were tested for the presence of anti-DFS70 antibodies using QUANTA Flash Õ DFS70 assay that used recombinant DFS70 (expressed in E.coli) coated onto paramagnetic beads and is designed for the BIO-FLASH Õ instrument (Biokit s.a., Barcelona, Spain). 22 The principles and protocols of the assay system have been previously described. 23, 24 
Statistical evaluation
Data were statistically evaluated using the Analyseit software (Version 3.9.1; Analyse-it Software, Ltd., Leeds, UK). Paired student t-test was performed to analyze the difference in results before and after immunoadsorption. Spearman's analysis was used to analyze the agreement between the CIA and IIF titers. For all statistical tests, p values less than 0.05 were considered significant.
Results
Development of a novel method for immunoadsorption of anti-DFS70 antibodies
To develop a novel method for the adsorption of anti-DFS70 antibodies as detected by IIF on HEp-2 cells, serum samples with anti-DFS70 antibodies were incubated with different concentrations of recombinant DFS70 antigen prior to incubation on HEp-2 cells (see Figure 1 ). With increasing concentrations of the purified DFS70 antigen, the reactivity measured by NOVA View on HEp-2 cells decreased (data not shown). Next we tested samples with anti-DFS70 antibodies identified by 
Immunoadsorption of anti-DFS70 antibodies
Subsequently, samples with anti-DFS70 antibodies were tested in parallel with and without recombinant DFS70 (HEp-2 Select) in the sample buffer and the LIUs were measured and compared. When using recombinant DFS70 in the sample buffer, the LIUs were significantly lower (median 87.0 vs. 14.0; p < 0.0001, Figure 2a ). 35/54 (64.8%) of samples tested positive by DFS70 CIA were found negative using recombinant DFS70 in the sample buffer. The decrease in LIUs was significantly higher in samples that tested positive for anti-DFS70 antibodies by QUANTA Flash DFS70 compared to the negative group (median delta 87.0 vs. 14.0 LIU; p < 0.0001, Figure 2b ). When samples were processed to mimic samples with mixed IIF staining patterns (DFS þ clinically relevant pattern), a different impact of anti-DFS70 antibodies on clinically relevant patterns was observed. Anti-DFS70 antibodies had a most noticeable masking effect on centromere pattern followed by nucleolar, speckled, and homogeneous ( Figure 3 ). After employing the new immunoadsorption method, all clinically relevant patterns were unmasked and the LIUs from NOVA View significantly decreased after inhibition (p < 0.0001).
ANA IIF survey
Out of the 125 survey responders, 58.0% had experience in reading IIF slides for more than 10 years, 21 
Discussion
Since anti-DFS70 antibodies are one of the most commonly misinterpreted ANA test results, our goal was to develop a method that would block anti-DFS70 antibodies from binding to their natural ligand on HEp-2 cells and, therefore, would suppress the DFS IIF staining and increase the specificity of the ANA test. Our data demonstrate that using recombinant DFS70 antigen as an immunoadsorbent in the assay buffer is an effective and efficient way to practically eliminate anti-DFS70 antibody staining of the widely used HEp-2 cell substrates for routine ANA testing. Anti-DFS70 antibodies have been historically associated with interstitial cystitis 10 and atopic dermatitis, 25 but they have also been described in various other diseases. 4 Although anti-DFS70 Figure 2 Inhibition of anti-DFS70 antibodies using recombinant DFS70 antigen. A total of 99 serum samples were tested in parallel with and without recombinant DFS70 in the assay buffer and the light intensity units (LIUs) were measured using NOVA View. A.) The LIUs were significantly lower when using DFS70 antigen in the assay buffer (paired t-test, p < 0.0001). B.) The decrease in signal (DFS delta) after immunoadsoprtion was significantly higher in samples positive for anti-DFS70 antibodies measured by QUANTA Flash DFS70 (median decrease 87.0 vs. 14.0 LIU; p < 0.0001).
antibodies have been reported in many conditions, a distinct clinical association remains unsubstantiated. However, anti-DFS70 antibodies have been proposed to be a useful biomarker for the exclusion of the diagnosis of an AARD. 8, 16, 17, 22 This suggestion has mainly been based on the observation that anti-DFS70 antibodies are more prevalent in HI than in AARD patients and that anti-DFS70 positive individuals did not develop AARD after clinical follow-up of four years. 15 Anti-DFS70 antibodies have been reported in approximately 1-5% of adult SLE patients, 16 but they are usually accompanied by other antibodies such as anti-dsDNA, anti-SS-A/Ro60 or anti-Sm, which may mask the DFS IIF staining pattern.
A positive ANA is part of the SLE classification criteria. 18 However, since anti-DFS70 antibodies are not associated with SLE and rarely found in isolation in SLE patients, those antibodies might reduce the specificity of the criteria. Therefore, including anti-DFS70 antibodies as exclusion criterion in the SLE classification criteria might be worth considering. For example the 11 th ACR criterion might be modified to: ''An abnormal titer of antinuclear antibody by IIF (excluding monospecific anti-DFS70 antibodies) or an equivalent assay at any point in time and in the absence of drugs''. However, it needs to be taken into account that revising the SLE criteria is challenging and requires extensive study and evaluation. Recently, the criteria were revisited and new criteria were proposed by the Systemic Lupus International Collaborating Clinics (SLICC) [Petri, 2012 [Petri, 2543 . Despite good performance of the new SLICC criteria, no changes have been made to the ACR criteria. Therefore, new biomarkers for SLE (i.e. anti-ribosomal P, anti-chromatin, anti-C1q) should be considered and validated together with anti-DFS70 antibodies for inclusion into future revised SLE classification criteria.
It has been reported that the frequency of anti-DFS70 antibodies in routine laboratories is within the range of other important AARD autoantibodies such as anti-dsDNA antibodies. 26, 27 In addition, it was found that most samples with DFS pattern identified by IIF had anti-DFS70 antibodies by CIA and/or ELISA which is consistent with our findings. However, since significant differences have been described between the staining patterns on HEp-2 cells from different manufacturers, 26, 28 it remains unclear if the DFS IIF pattern can be recognized with similar accuracy using slides from a variety of manufacturers. Such potential variations might be attributed to the fixation methods, culture conditions, and/or other processes used for manufacturing the cell substrates. 28 Another variable to consider is the technical acumen of the laboratory personnel in identifying the DFS pattern. Although previous data 22 indicate that the DFS pattern can be identified on slides from a number of ANA kit manufacturers, more samples need to be analyzed to arrive at a conclusion, especially since conflicting results have been published. 28 Since a positive ANA test result is an important component in the triage and diagnosis of patients with possible AARD, ANA-HEp-2 testing outside a proper clinical setting may yield a sizable number of ANA-positive apparently HI, causing concern and anxiety in patients and physicians 15, 29 and may lead to prescribing inappropriate and potentially toxic therapeutics. 20, 30 This concern becomes even more important with the knowledge that autoantibodies often precede the clinical onset of AARD by many years. [31] [32] [33] Hence, samples with DFS staining pattern identified by IIF should be tested for anti-DFS70 antibodies by a specific assay (i.e. ELISA or CIA) and the result should be explained in the laboratory report. In addition, it is advisable that clinicians should not over-interpret positive ANA results caused by anti-DFS70 antibodies but should focus on the clinical signs and symptoms complemented by the detection of other disease-specific autoantibodies.
Historically, when the ANA HEp-2 test became available in the 1970s, mostly rheumatologists ordered this test. With the eventual recognition that many other diseases with autoimmune features are also associated with ANAs, a broader range of clinical disciplines now order the ANA test. This change in test referral pattern has tremendous consequences for the post-test probability of disease since screening tests with limited specificity (such as IIF ANA) are strongly affected when the pretest probability in a given population decreases. In this study we summarize the development of a novel immunoadsorption immunoassay that allows for the inhibition of anti-DFS70 antibodies in the widely used ANA test on HEp-2 substrates. Our data confirm that the immunoadsorption effectively blocks anti-DFS70 antibodies and unmasks the clinically relevant patterns. The mixed pattern experiment demonstrated how mixed pattern with DFS70 can complicate the ANA interpretation and that immunoadsorption can bring clarity to HEp-2 ANA results. Additionally, the international ANA IIF survey reconfirmed the mixed pattern experiment by involving expert IIF readers worldwide to identify the DFS pattern as well as this pattern mixed other clinically relevant patterns. The results of the survey showed that while the established clinically relevant patterns were easy to identify, many responders incorrectly identified the DFS pattern as speckled or homogeneous and there was widespread disagreement for the mixed pattern images where only 10.0% of responders chose the correct answer. Adsorption of anti-DFS70 antibodies prior to the ANA IIF test significantly reduces the false positive rate and thus overcomes one of the major limitations of ANA using HEp-2 cells. This will most likely lead to a higher diagnostic accuracy of the test and avoids concern and anxiety in patients and physicians. Furthermore, the risk of inappropriate treatment might be reduced. Since this might lead to contradictory results between different laboratories (depending on which methods are used for ANA testing), a clear description of the method used should be included in any test report provided to clinicians, accompanied with a detailed description.
